<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Peramivir: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Peramivir: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Peramivir: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12284" href="/d/html/12284.html" rel="external">see "Peramivir: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13045" href="/d/html/13045.html" rel="external">see "Peramivir: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26819872"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rapivab</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871115"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rapivab</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9523406"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent;</li>
<li>
                        Neuraminidase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F9523429"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a6af45f-3353-4fff-8bdb-13bb7aed92b7">Influenza, acute, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, acute, uncomplicated:</b>
<b>IV:</b> 600 mg as a single dose; initiate within 2 days of onset of symptoms of influenza.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="414e1dca-d6f7-418a-bae1-11e57fd029e1">Influenza, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, hospitalized patients (alternative agent) (off-label use): IV:</b> 600 mg once daily for up to 5 to 10 days (CDC 2020a; de Jong 2014; Ison 2014; Kohno 2011). <b>Note:</b> Due to insufficient data on use of peramivir for treatment of hospitalized patients with influenza, only consider for patients who cannot tolerate or absorb oral or enterically-administered oseltamivir due to gastric stasis, malabsorption, or GI bleeding (CDC 2020a).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990639"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated influenza: </i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 49 mL/minute: 200 mg as a single dose</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 29 mL/minute: 100 mg as a single dose</p>
<p style="text-indent:-2em;margin-left:6em;">ESRD requiring intermittent hemodialysis (IHD): 100 mg as a single dose, administered after dialysis</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hospitalized patients with influenza (FDA 2009):</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: 600 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 31 to 49 mL/minute: 150 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 30 mL/minute: 100 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute (not on renal replacement therapy): 100 mg once daily on day 1, then 15 mg once daily beginning on day 2</p>
<p style="text-indent:-2em;margin-left:6em;">ESRD requiring intermittent hemodialysis (IHD): 100 mg on day 1, then 100 mg given 2 hours after each dialysis session</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Pharmacokinetic data indicate that peramivir is efficiently cleared by CRRT due to high sieving coefficient and low protein binding (Bazan 2010; Bentley 2014; Scheetz 2011). One suggested method for determining the dose of peramivir while on CRRT, assuming a sieving coefficient of 100% and negligible protein binding, is to estimate the patient’s total clearance based on the following equation and refer to the above renal dosage adjustments for dose selection (FDA 2009):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Total clearance</b> = Residual renal function (mL/minute) + CRRT clearance (CL<sub>CRRT</sub>) (mL/minute)</p>
<p style="text-indent:-2em;margin-left:8em;">CL<sub>CRRT</sub> can be determined as follows:</p>
<p style="text-indent:-2em;margin-left:10em;">CVVH/Continuous arteriovenous hemofiltration (CAVH)/Slow continuous ultrafiltration (SCUF): Use ultrafiltration rate (mL/minute)</p>
<p style="text-indent:-2em;margin-left:10em;">CAVHD/CVVHD: Use dialysate flow rate (mL/minute)</p>
<p style="text-indent:-2em;margin-left:10em;">Continuous arteriovenous hemodialysis (CAVHDF)/CVVHDF: Use total of ultrafiltration rate and dialysate flow rate (mL/minute)</p></div>
<div class="block doha drugH1Div" id="F50987809"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); however, not significantly metabolized hepatically.</p></div>
<div class="block doe drugH1Div" id="F9832452"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F50665288"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13045" href="/d/html/13045.html" rel="external">see "Peramivir: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65befa1b-0784-4ebb-ad57-1d360eed144b">Influenza, treatment; acute, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, treatment; acute, uncomplicated:</b>
<b>Note: </b>Administer within 2 days of onset of symptoms of influenza.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: IV: 12 mg/kg as a single dose; maximum dose: 600 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV: 600 mg as a single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2dfadb70-7d79-41a9-9fe9-cf4a9dc14c7c">Influenza, treatment; hospitalized, high risk and/or epidemic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, treatment</b>
<b>; hospitalized, high risk and/or epidemic (alternate agent): </b>Limited data available; efficacy results variable; optimal dosing not established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Peramivir should be considered in patients who cannot tolerate or absorb oseltamivir (CDC 2021b). During the 2009 influenza season, peramivir was given as part of an Emergency Use Authorization in the United States for patients with pandemic A (H1N1) 2009 virus (FDA 2009). Subsequently, it has been studied but is not approved for use in hospitalized patients and/or patients with complicated influenza (de Jong 2014; Sugaya 2012; Witcher 2019). In a small pharmacokinetic study, 11 critically ill children demonstrated faster clearance than previously reported; however, additional studies are needed (Cies 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">29 to 30 days of life: 6 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014); others have used 10 mg/kg/dose once daily (Komeda 2015; Sugaya 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">31 to 90 days of life: 8 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014); others have used 10 mg/kg/dose once daily (Komeda 2015; Sugaya 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">91 to 180 days of life: 10 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014; Komeda 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">181 days of life through 5 years: 12 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata 2014); others have used 10 mg/kg/dose once daily (Komeda 2015; Sugaya 2012); maximum daily dose: 600 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 17 years: 10 mg/kg/dose once daily for 5 to 10 days (FDA 2009; Hata, 2014; Komeda 2015); maximum daily dose: 600 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">≥18 years: 600 mg once daily for 5 to 10 days (Hata 2014).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51152602"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated influenza: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months and Children &lt;2 years: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Based on experience with older children and adolescents, dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to 49 mL/minute:</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥2 years: 4 mg/kg as a single dose; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: 200 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 10 to 29 mL/minute:</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥2 years: 2 mg/kg as a single dose; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: 100 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">End-stage renal disease requiring hemodialysis:</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥2 years: 2 mg/kg as a single dose; maximum dose: 100 mg/dose, administered after dialysis.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: 100 mg as a single dose; administered after dialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hospitalized (high-risk and/or epidemic) patients with influenza:</i> Limited data available: Dosing adjustment based on recommendations from H1N1 epidemic 2009 to 2010 (FDA 2009):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;18 years: <b>Note:</b> Dosage adjustment based on renal function estimated using the Schwartz equation.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 31 to 49 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">29 to 30 days of life: 1.5 mg/kg/dose once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">31 to 90 days of life: 2 mg/kg/dose once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">91 to 180 days of life: 2.5 mg/kg/dose once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">181 days of life through 5 years: 3 mg/kg/dose once daily for 5 to 10 days; maximum dose: 150 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 17 years: 2.5 mg/kg/dose once daily for 5 to 10 days; maximum dose: 150 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 10 to 30 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">29 to 30 days of life: 1 mg/kg/dose once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">31 to 90 days of life: 1.3 mg/kg/dose once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">91 to 180 days of life: 1.6 mg/kg/dose once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">181 days of life through 5 years: 1.9 mg/kg/dose once daily for 5 to 10 days; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 17 years: 1.6 mg/kg/dose once daily for 5 to 10 days; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup> (<b>not</b> on intermittent hemodialysis [HD] or continuous renal replacement therapy [CRRT]):</p>
<p style="text-indent:-2em;margin-left:10em;">29 to 30 days of life: 1 mg/kg/dose on day 1, followed by 0.15 mg/kg/dose once daily for a total of 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">31 to 90 days of life: 1.3 mg/kg/dose on day 1, followed by 0.2 mg/kg/dose once daily for a total of 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">91 to 180 days of life: 1.6 mg/kg/dose on day 1, followed by 0.25 mg/kg/dose once daily for a total of 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:10em;">181 days of life through 5 years: 1.9 mg/kg/dose on day 1 (maximum dose day 1: 100 mg/dose), followed by 0.3 mg/kg/dose once daily for a total of 5 to 10 days; maximum dose: 15 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 17 years: 1.6 mg/kg/dose on day 1 (maximum dose day 1: 100 mg/dose), followed by 0.25 mg/kg/dose once daily for a total of 5 to 10 days; maximum dose: 15 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodialysis (intermittent) CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">29 to 30 days of life: 1 mg/kg/dose on day 1, followed by 1 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only.</b></p>
<p style="text-indent:-2em;margin-left:10em;">31 to 90 days of life: 1.3 mg/kg/dose on day 1, followed by 1.3 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only.</b></p>
<p style="text-indent:-2em;margin-left:10em;">91 to 180 days of life: 1.6 mg/kg/dose on day 1, followed by 1.6 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only.</b></p>
<p style="text-indent:-2em;margin-left:10em;">181 days of life through 5 years: 1.9 mg/kg/dose on day 1, followed by 1.9 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b>; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 17 years: 1.6 mg/kg/dose on day 1, followed by 1.6 mg/kg/dose given 2 hours after each HD session <b>on dialysis days only</b>; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CRRT: Limited data exist. Estimate total clearance by calculating CRRT clearance (CL<sub>CRRT</sub>) depending on CRRT modality used (eg, CVVHD, slow continuous ultrafiltration [SCUF]), plus any residual renal function, and adjust dosage according to CrCl recommendation.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: <b>Note:</b> Dosage adjustment based on renal function estimated using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥50 mL/minute: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 31 to 49 mL/minute: 150 mg once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 10 to 30 mL/minute: 100 mg once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;10 mL/minute (not on renal replacement therapy): 100 mg on day 1, followed by 15 mg once daily for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodialysis (HD): 100 mg on day 1, followed by 100 mg given 2 hours after each HD session on dialysis days only.</p></div>
<div class="block dohp drugH1Div" id="F51152603"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, not significantly metabolized hepatically.</p></div>
<div class="block adr drugH1Div" id="F27106543"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">As reported with adult patients, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose (&gt;160 mg/dL: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (4%), diarrhea (8%), vomiting (children &amp; adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (children &amp; adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic and oncologic: Neutropenia (&lt;1 x 10<sup>9</sup>/L: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&gt;2.5 x ULN: 3%), increased serum aspartate aminotransferase (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (≥6 x ULN: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, exfoliative dermatitis, skin rash, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior, delirium, hallucination</p></div>
<div class="block coi drugH1Div" id="F9523426"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity or anaphylaxis to peramivir or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F9523946"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Rare serious skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome) have been reported. If skin reactions are suspected or occur, discontinue infusion immediately and institute appropriate supportive treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity reactions (eg, anaphylaxis) have been reported. Discontinue infusion immediately and institute appropriate supportive treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric events: Rare occurrences of neuropsychiatric events (including abnormal behavior, delirium, and hallucinations), including fatalities have been reported, primarily among pediatric patients. Onset is often abrupt and subsequent resolution is rapid. These events may occur in patients with encephalitis, encephalopathy, or in uncomplicated influenza. Closely monitor for signs of abnormal behavior.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Elimination is primarily renal; dosage adjustment is required in patients with CrCl &lt;50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Emergence of resistance substitutions or other factors (eg, viral virulence) could decrease drug effectiveness. Consider available information on influenza drug susceptibility patterns/treatment effects when using; efficacy in patients with serious influenza requiring hospitalization has not been established. Has not been shown to prevent secondary serious bacterial infections occurring during influenza course; if bacterial infections occur, treat with antibiotics as appropriate.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878769"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric trials, most frequently reported adverse effects included diarrhea and abnormal behavior (Komeda 2015). Abnormal behavior, particularly of a moderate severity, may be more likely with peramivir as compared to other neuraminidase inhibitors in patients 5 to 19 years of age; data are limited (Nakamura 2015; Sugawara 2020).</p></div>
<div class="block foc drugH1Div" id="F9524105"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapivab: 200 mg/20 mL (20 mL)</p></div>
<div class="block geq drugH1Div" id="F26819871"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26844478"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Rapivab Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $19.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871116"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rapivab: 200 mg/20 mL (20 mL)</p></div>
<div class="block adm drugH1Div" id="F26726884"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer as an IV infusion over 15 to 30 minutes.</p></div>
<div class="block admp drugH1Div" id="F52614442"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: For IV use only, do not administer IM. Administer diluted dose IV over 15 to 30 minutes; in some pediatric studies, infusion times up to 60 minutes have been used (Komeda 2015; Sugaya 2012).</p></div>
<div class="block use drugH1Div" id="F26702041"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza, acute uncomplicated:</b> Treatment of acute, uncomplicated influenza in patients ≥6 months of age who have been symptomatic ≤2 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Efficacy is based on clinical trials in which influenza A was the predominant virus; a limited number of subjects with influenza B have been studied.</p></div>
<div class="block off-label drugH1Div" id="F50973396"><span class="drugH1">Use: Off-Label: Adult</span><p>Influenza, hospitalized patients</p></div>
<div class="block cyt drugH1Div" id="F26736612"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9613155"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid administration of live influenza virus vaccine (LAIV) within 2 weeks before or 48 hours after administration of antiviral agents. Consider avoiding LAIV if peramivir was given within the last 5 days or baloxavir was given within the last 17 days.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F26726821"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to the use of peramivir for the treatment of influenza in pregnancy is limited (Hernandez 2011; Komeda 2016; Sorbello 2012). However, pregnant and postpartum patients (≤2 weeks after delivery) have a higher risk for complications from influenza, including preterm delivery, pneumonia, admission to a hospital or intensive care unit, and maternal and fetal death. Underlying maternal medical conditions increase these risks (ACOG 2018; CDC 2020a).</p>
<p style="text-indent:0em;margin-top:2em;">Based on information from one case, the pharmacokinetics of peramivir may be changed with pregnancy (Clay 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Peramivir is not the preferred neuraminidase inhibitor for the treatment of influenza during pregnancy, however it may be used as an alternative agent when otherwise appropriate (ACOG 2018; CDC 2020a; CDC 2020b). Pregnant patients with known or suspected influenza can be treated with antiviral medications, regardless of trimester, vaccination status, or laboratory test results (ACOG 2018; CDC 2020a; CDC 2020b).</p>
<p style="text-indent:0em;margin-top:2em;">An algorithm is available for the treatment of pregnant patients with known or suspected influenza (ACOG 2018). Refer to the Centers for Disease Control and Prevention recommendations recommendations for treatment updates based on resistance patterns (ACOG 2018; CDC 2020a).</p></div>
<div class="block brc drugH1Div" id="F26726823"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if peramivir is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Until additional information becomes available, peramivir is not the preferred neuraminidase inhibitor for the treatment of influenza in patients who are breastfeeding. Infectious patients should take precautions to avoid influenza transmission to the breastfed infant (CDC 2021a).</p></div>
<div class="block mop drugH1Div" id="F26726887"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Baseline BUN and serum creatinine, neurologic abnormalities (eg, abnormal behavior), rash after administration.</p></div>
<div class="block pha drugH1Div" id="F9523513"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Peramivir, a cyclopentane analogue, selectively inhibits the influenza virus neuraminidase enzyme, preventing the release of viral particles from infected cells.</p></div>
<div class="block phk drugH1Div" id="F26726876"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 12.56 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;30%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not significantly metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Low (investigational agent) (Hata 2014)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~20 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~90% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51159996"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased with increasing degree of renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Pharmacokinetics in children 2 to 17 years of age with uncomplicated influenza were similar to adults. In infants and children 6 months to &lt;2 years of age, maximum concentration and initial 3-hour exposure were lower than in healthy adults, but the difference is not considered clinically significant (manufacturer's labeling). Critically ill children may demonstrate increased clearance and shorter elimination half-life as compared to children with uncomplicated influenza (Cies 2019).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26999114"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Rapivab</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Peramivir and Sodium Chloride</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alpivab</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Rapiacta</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rapiacta</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Innonflu | Peramiflu | Peramiflu premix | Peraonce | Peraonce premix</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rapivab</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Rapiacta</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30247362">
<a name="30247362"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 753: assessment and treatment of pregnant women with suspected or confirmed influenza. <i>Obstet Gynecol</i>. 2018;132(4):e169-e173. doi:10.1097/AOG.0000000000002872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/30247362/pubmed" id="30247362" target="_blank">30247362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20874039">
<a name="20874039"></a>Bazan JA, Bauer KA, Hollister AS, et al. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy. <i>Pharmacotherapy.</i> 2010;30(10):1016-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/20874039/pubmed" id="20874039" target="_blank">20874039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25345428">
<a name="25345428"></a>Bentley ML, Hollistera AS, Hansenb AC, Smith JA, Cain JS. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. <i>Int J Clin Pharmacol Ther</i>. 2014;52(12):1105-11. doi: 10.5414/CP202161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/25345428/pubmed" id="25345428" target="_blank">25345428</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR</i>. 2011; 60(1):1-28.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Breastfeeding. Influenza (Flu). <a href="https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/influenza.html" target="_blank">https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/influenza.html</a>. Published January 12, 2021a. Accessed on January 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC2020">
<a name="CDC2020"></a>Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Published November 30, 2020a. Accessed December 31, 2020.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Published January 25, 2021b. Accessed February 12, 2021.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. <a href="https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm" target="_blank">https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm</a>. Published November 30, 2020b. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference">
                  Cies JJ, Moore WS 2nd, Enache A, Chopra A. Peramivir for influenza A and B viral infections: a pharmacokinetic case series. <i>Pharmacotherapy</i>. 2019;39(11):1060-1065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/31514223/pubmed" id="31514223" target="_blank">31514223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21768855">
<a name="21768855"></a>Clay PG, Adiga RB, Taylor TA, Alsup R, Gerk PM, McRae M. Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza. <i>Obstet Gynecol</i>. 2011118(2 Pt 2):463-467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/21768855/pubmed" id="21768855" target="_blank">21768855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25115871">
<a name="25115871"></a>de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. <i>Clin Infect Dis</i>. 2014;59(12):e172-e185. doi: 10.1093/cid/ciu632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/25115871/pubmed" id="25115871" target="_blank">25115871</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration (FDA). Peramivir emergency use authorization, fact sheet for health care providers. November 19, 2009.</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration. Emergency use authorization of peramivir IV. Fact sheet for health care providers. November 19, 2009. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf" target="_blank">https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf</a>. Accessed January 19, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25368514">
<a name="25368514"></a>Hata A, Akashi-Ueda R, Takamatsu K, Matsumura T. Safety and efficacy of peramivir for influenza treatment. <i>Drug Des Devel Ther</i>. 2014;8:2017-2038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/25368514/pubmed" id="25368514" target="_blank">25368514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19067613">
<a name="19067613"></a>Hayden F, “Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?” <i>Clin Infect Dis</i>, 2009, 48 Suppl 1:3-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/19067613/pubmed" id="19067613" target="_blank">19067613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21367722">
<a name="21367722"></a>Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.<i> Clin Infect Dis</i>. 2011;52(6):695-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/21367722/pubmed" id="21367722" target="_blank">21367722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23985625">
<a name="23985625"></a>Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. <i>Antivir Ther</i>. 2014;19(4):349-361. doi: 10.3851/IMP2680.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/23985625/pubmed" id="23985625" target="_blank">23985625</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kohno S, MY Yen, HJ Cheong, et al, “Single-Intravenous Peramivir vs Oral Oseltamivir to Treat Acute, Uncomplicated Influenza in the Outpatient Setting: A Phase III Randomized, Double-Blind Trial,” ICAAC 2009, Abstract V-537a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21464252">
<a name="21464252"></a>Kohno S, Kida H, Mizuguchi M, et al; S-021812 Clinical Study Group. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. <i>Antimicrob Agents Chemother</i>. 2011;55(6):2803-2812. doi: 10.1128/AAC.01718-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/21464252/pubmed" id="21464252" target="_blank">21464252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25523716">
<a name="25523716"></a>Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation. <i>J Infect Chemother</i>. 2015;21(3):194-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/25523716/pubmed" id="25523716" target="_blank">25523716</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Komeda T, Ishii S, Itoh Y, Sanekata M, Yoshikawa T, Shimada J. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors. <i>J Infect Chemother</i>. 2016;22(10):677-684. doi:10.1016/j.jiac.2016.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/27497712/pubmed" id="27497712" target="_blank">27497712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21074132">
<a name="21074132"></a>Louie JK, Jamieson DJ, Rasmussen SA, et al, "2009 Pandemic Influenza A (H1N1) Virus Infection in Postpartum Women in California," <i>Am J Obstet Gynecol</i>, 2011, 204(2):144.e1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/21074132/pubmed" id="21074132" target="_blank">21074132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24276847">
<a name="24276847"></a>Louie JK, Yang S, Samuel MC, Uyeki TM, Schechter R. Neuraminidase inhibitors for critically ill children with influenza. <i>Pediatrics</i>. 2013;132(6):e1539-1545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/24276847/pubmed" id="24276847" target="_blank">24276847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22768265">
<a name="22768265"></a>Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. <i>PLoS One</i>. 2012;7(6):e40261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/22768265/pubmed" id="22768265" target="_blank">22768265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nakamura Y, Sugawara T, Ohkusa Y, et al. Life-threatening abnormal behavior incidence in 10-19 year old patients administered neuraminidase inhibitors. <i>PLoS One</i>. 2015;10(7):e0129712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/26132729/pubmed" id="26132729" target="_blank">26132729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17570104">
<a name="17570104"></a>Ong AK and Hayden FG, “John F. Enders Lecture 2006: Antivirals for Influenza,” <i>J Infect Dis</i>, 2007, 196(2):181-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/17570104/pubmed" id="17570104" target="_blank">17570104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22065262">
<a name="22065262"></a>Randolph AG, Vaughn F, Sullivan R, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. <i>Pediatrics</i>. 2011;128(6):e1450-1458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/22065262/pubmed" id="22065262" target="_blank">22065262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rapivab.1">
<a name="Rapivab.1"></a>Rapivab (peramivir) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22116989">
<a name="22116989"></a>Scheetz MH, Griffith MM, Ghossein C, Hollister AS, Ison MG. Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. <i>Ann Pharmacother</i>. 2011;45(12):e64. doi: 10.1345/aph.1Q437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/22116989/pubmed" id="22116989" target="_blank">22116989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22491501">
<a name="22491501"></a>Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. <i>Clin Infect Dis</i>. 2012;55(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/22491501/pubmed" id="22491501" target="_blank">22491501</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sugawara T, Ohkusa Y, Taniguchi K, Miyazaki C, Momoi MY, Okabe N. Association of moderately abnormal behavior and administered neuraminidase inhibitors. <i>Drug Discov Ther</i>. 2020;14(1):50-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/32101820/pubmed" id="32101820" target="_blank">32101820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22024821">
<a name="22024821"></a>Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. <i>Antimicrob Agents Chemother</i>. 2012;56(1):369-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/22024821/pubmed" id="22024821" target="_blank">22024821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20491974">
<a name="20491974"></a>Thomas B, Hollister AS, Muczynski KA. Peramivir Clearance in Continuous Renal Replacement Therapy. <i>Hemodialysis International.</i> 2010;14(3):339-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/20491974/pubmed" id="20491974" target="_blank">20491974</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Witcher R, Tracy J, Santos L, Chopra A. Outcomes and adverse effects with peramivir for the treatment of influenza H1N1 in critically ill pediatric patients. <i>J Pediatr Pharmacol Ther</i>. 2019;24(6):497-503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/31719811/pubmed" id="31719811" target="_blank">31719811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28716363">
<a name="28716363"></a>Yeh CY, Wang FD, Chuang YC, et al. Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units. <i>J Microbiol Immunol Infect</i>. 2017. pii: S1684-1182(17)30077-30074. doi: 10.1016/j.jmii.2017.06.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/28716363/pubmed" id="28716363" target="_blank">28716363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25946636">
<a name="25946636"></a>Yoo JW, Choi SH, Huh JW, Lim CM, Koh Y, Hong SB. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza. <i>J Med Virol</i>. 2015;87(10):1649-1655. doi: 10.1002/jmv.24232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/25946636/pubmed" id="25946636" target="_blank">25946636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22491506">
<a name="22491506"></a>Yu Y, Garg S, Yu PA, et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. <i>Clin Infect Dis</i>. 2012;55(1):8-15. doi: 10.1093/cid/cis352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/peramivir-drug-information/abstract-text/22491506/pubmed" id="22491506" target="_blank">22491506</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zachary KC. Treatment of seasonal influenza in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed on January 19, 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9527 Version 136.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
